Effectiveness of Pretreatment Letrozole Versus Misoprostol Alone in Missed Abortion
NCT ID: NCT04194658
Last Updated: 2019-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
150 participants
INTERVENTIONAL
2020-01-31
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives :
To compare the effect of a combination of letrozole with misoprostol versus misoprostol alone in successful induction of medical abortion.
Study population \& Sample size 150 women will be recruited. Women included will be \> 18 years with singleton pregnancy of gestational age ≤ 20 weeks having missed abortion. They will be excluded if they have prior CS, twin pregnancy, allergy to letrozole or liver problems.
Study Design :
A randomized controlled trial in which patients will be divided into 2 groups; case group \& control group. Each group will contain 75 patients.
Methods :
Case group will receive pretreatment letrozole 12.5 mg for 2 days while control group will receive only misoprostol. Both groups will receive misoprostol in a dosage according to the ACOG guidelines based on gestational age.
Possible Risk (s) to study population :
Major risks (Sepsis, considerable vaginal bleeding leading to hemodynamic instability or necessitating blood transfusion). Minor risks (Nausea, diarrhea, headache, weakness, hot flushes).
Outcome parameter (s):
Successful medical abortion i.e. complete abortion with no need for surgical curettage within one week from the 1st dose of misoprostol.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Abortion management is one of the most important issues in gyne¬cology. According to the WHO abortion accounts for about 8% of maternal mortality worldwide. The term 'abortion' has become synonymous with induced abortion which is an intentional termination of pregnancy but it also includes spontaneous abortion.
Induced abortion is thus one of the most commonly investigated topics in gynecology as means to achieve safe abortion in order to reduce associated maternal morbidity \& mortality.
Abortion is defined as the termination of a pregnancy before the 20th week of pregnancy or termina¬tion of pregnancy before the fetus weighing 500 g.
Surgical intervention is the definitive treatment for abortion. However, it is invasive and is not necessary for all females. Curettage may be avoided via expectation and medi¬cal treatment.
Misoprostol, a synthetic analogue of natural prostaglandin E1, is exten-sively used for early termination of pregnancy, therapeutic abortion, treatment of incomplete or missed abortion. It results in abortion by ripening of the cervix \& stimulating the myometrium. Misoprostol abortion rate is less than 90% in most studies and it has different side effects.
Progesterone is an essential component to establish and maintain pregnancy. It is responsible for the transformation of the endometrium from a proliferative to a secretory state. In addition, it has a role in relaxation of the uterus and prevention of cervical dilatation.
Estrogen is also important in the maintenance of pregnancy, although less evidence exists for this. Aromatase enzyme is essential for its production via aromatization of androgens.
During early pregnancy, the corpus luteum is the main source of estrogen and progesterone. It is initially maintained by luteinizing hormone (LH) from the anterior pituitary, then after implantation human chorionic gonadotropin (hCG) from the trophoblastic cells takes over the role of LH. This continues until the 7th week of pregnancy, when the placenta becomes the main source of hormone production.
Pharmacological agents that can reduce or block the actions of progesterone or estrogen may therefore have a role in medical abortion.
Mifepristone, a progesterone antagonist, is widely used for medical abortion in countries where it is available. The complete abortion rate of the sequential regimen using 200 mg of oral mifepristone, followed 36-48 h later by a single dose of 800 µg of vaginal misoprostol, is over 95% in pregnancies of less than 9 weeks' gestation.
The widespread use of mifepristone is limited by the fact that it is expensive and not available in many countries. Therefore a cheaper and easily available alternative needs to be found.
Letrozole, a non-steroidal aromatase inhibitor, is most commonly used in hormone-sensitive breast cancer. It reversibly and competitively bonds with the iron in cytochrome P450 and prevents estrogen production by the enzyme aromatase.
Since estrogens are necessary for continuation of the pregnancy, we hypothesize that acute suppression of the serum estradiol concentration by letrozole in human pregnancy would affect the function of corpus and/or placenta thus facilitating termination of pregnancy.
Objectives:
To compare the effect of a combination of letrozole with misoprostol versus misoprostol alone in successful induction of medical abortion.
Study Design:
A randomized controlled trial involving 150 women will be performed. They will be randomly divided into 2 groups; each group contains 75 participants.
Case group will receive pretreatment letrozole 12.5 mg for 2 days while control group will receive only misoprostol. Both groups will receive misoprostol in a dosage according to the ACOG guidelines based on gestational age.
The study performed will be a phase 2 clinical trial. The study will be performed in Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University.
Patient \& Methods:
Sample size:
Sample size was calculated to prevent type II error. According to Naghshineh and coworkers (2015), complete abortion rates among case subjects was 76.7 % versus 42.6 % in the control subjects. Calculation showed we need 51women in each arm to be able to reject with a probability of 95% the null hypothesis that the rates for the case and control groups are equal. The type I error probability associated with this test for the null hypothesis was 0.05. Additionally, to compensate for subjects declining to participate or lost to follow-up, we recruited 75 women in each arm.
Statistical analysis The collected data will be tabulated and analyzed using appropriate statistical tests.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case group
Case group will receive pretreatment letrozole 12.5 mg for 2 days before administration of misoprostol in a dosage according to ACOG guidelines based on gestational age.
Letrozole 2.5mg
Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
Control group
Control group will receive only misoprostol in a dosage according to ACOG guidelines based on gestational age.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Letrozole 2.5mg
Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primigravida or multigravida.
* Gestational age ≤ 20 weeks.
* Missed abortion.
Exclusion Criteria
* Twin pregnancy.
* Previous cesarean section.
* Allergy to letrozole or misoprostol.
* Liver cirrhosis or severe liver impairment.
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amr Fathy Zaky
Assistant Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mostafa Seleem, MD
Role: STUDY_DIRECTOR
Cairo University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Yung SSF, Lee VCY, Chiu PCN, Li HWR, Ng EHY, Yeung WSB, Ho PC. The effect of 7 days of letrozole pretreatment combined with misoprostol on the expression of progesterone receptor and apoptotic factors of placental and decidual tissues from first-trimester abortion: a randomized controlled trial. Contraception. 2016 Apr;93(4):323-330. doi: 10.1016/j.contraception.2015.12.005. Epub 2015 Dec 19.
Naghshineh E, Allame Z, Farhat F. The effectiveness of using misoprostol with and without letrozole for successful medical abortion: A randomized placebo-controlled clinical trial. J Res Med Sci. 2015 Jun;20(6):585-9. doi: 10.4103/1735-1995.165964.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Letrozole in missed abortion
Identifier Type: -
Identifier Source: org_study_id